Generic lialda?

See the DrugPatentWatch profile for lialda

What are generic alternatives to Lialda (mesalamine)?

Lialda is a brand-name medication containing mesalamine, an aminosalicylate anti-inflammatory used primarily to treat ulcerative colitis and Crohn's disease [1]. With patent expirations, generic versions of Lialda have become available.

When will the Lialda patent expire?

Mesalamine's patent expiration dates vary by country; according to PatentWatch website - a source to track patents [2] and here , the key patent for mesalamine expired in 2016 in the United States, allowing generic versions of the medication to enter the market.

Which generic Lialda medications are available?

Several generic versions of mesalamine have been approved by the United States Food and Drug Administration (FDA) and are available from various manufacturers [3]. Some examples include:

* Mesalamine 0.5g tablets and capsules by Sandoz
* Mesalamine 1.2g tablets by Actavis
* Mesalamine 1.6g capsules by Teva

How do generic Lialda medications compare?

Generic medications are equivalent to their brand-name counterparts in terms of active ingredients, strength, dosage form, and route of administration [4]. However, some differences may exist in inactive ingredients, pricing, and packaging. Patients should consult their healthcare providers or pharmacists to determine the best generic alternative for their specific needs.

Are biosimilars of Lialda available?

Biosimilars of Lialda are not yet available. Biosimilars must undergo a separate regulatory approval process and have not yet entered the market for this specific medication.

Sources:

[1] Mayo Clinic. (2022). Mesalamine (Oral Route). Retrieved from https://www.mayoclinic.org/drugs-supplements/mesalamine-oral-route/description/drg-20065644

[2] Generic and Biosimilar Medications, PatentWatch website, https://www.drugpatentwatch.com/

[3] FDA Approved Generic Medications, US Food and Drug Administration website. https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

[4] Generic and Biosimilar Medications, American Society of Health-System Pharmacists website. https://www.ashp.org/-/media/assets/policy-guidelines/docs/guidelines/guidelines-generic-and-biosimilar-medication-2016.ashx?la=en&dmc=1&ts=20220623T1242354213